75 related articles for article (PubMed ID: 21507170)
21. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
[TBL] [Abstract][Full Text] [Related]
22. A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine.
Malingré MM; Godschalk PC; Klein SK
Br J Clin Pharmacol; 2012 Jul; 74(1):205-6. PubMed ID: 22122271
[No Abstract] [Full Text] [Related]
23. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH
J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141
[TBL] [Abstract][Full Text] [Related]
24. [Hallucinosis as side effect of voriconazole].
Flox Benítez G; Rondón Fernández P; Quero Escalada M; Fernández Ballesteros A
Rev Clin Esp; 2005 Dec; 205(12):632-3. PubMed ID: 16527191
[No Abstract] [Full Text] [Related]
25. Factors affecting voriconazole plasma concentrations in patients with invasive fungal infections.
Kim DY; Park HJ; Lee YJ
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):209-16. PubMed ID: 24424111
[TBL] [Abstract][Full Text] [Related]
26. Hallucinations during voriconazole therapy: who is at higher risk and could benefit from therapeutic drug monitoring?
Pea F; Viale P
Ther Drug Monit; 2009 Feb; 31(1):135-6. PubMed ID: 19077926
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
28. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics.
Rengelshausen J; Banfield M; Riedel KD; Burhenne J; Weiss J; Thomsen T; Walter-Sack I; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2005 Jul; 78(1):25-33. PubMed ID: 16003289
[TBL] [Abstract][Full Text] [Related]
29. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.
Yang ZF; Cui HW; Hasi T; Jia SQ; Gong ML; Su XL
Genet Mol Res; 2010 Sep; 9(3):1844-51. PubMed ID: 20845310
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Ramaraj R
Lancet; 2009 Apr; 373(9670):1172; author reply 1172-3. PubMed ID: 19345827
[No Abstract] [Full Text] [Related]
32. Influence of CYP3A and CYP2C19 genetic polymorphisms on the pharmacokinetics of cilostazol in healthy subjects.
Yoo HD; Park SA; Cho HY; Lee YB
Clin Pharmacol Ther; 2009 Sep; 86(3):281-4. PubMed ID: 19516253
[TBL] [Abstract][Full Text] [Related]
33. CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis.
Bozdag G; Alp A; Saribas Z; Tuncer S; Aksu T; Gurgan T
Reprod Biomed Online; 2010 Feb; 20(2):286-90. PubMed ID: 20113968
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Bhattacharyya S; Rakhit R
Lancet; 2009 Apr; 373(9670):1171; author reply 1172-3. PubMed ID: 19345825
[No Abstract] [Full Text] [Related]
35. Cytochrome P-450 polymorphisms and response to clopidogrel.
Miao J; Liu R; Li Z
N Engl J Med; 2009 May; 360(21):2250-1. PubMed ID: 19469033
[No Abstract] [Full Text] [Related]
36. [Case of pulmonary aspergillosis associated with inappropriate antidiuretic hormone syndrome caused by voriconazole therapy].
Isobe K; Muraoka S; Sugino K; Yamazaki Y; Kikuchi N; Hamanaka N; Takai Y; Shimizu K; Kimura K; Hiroi N; Shibuya K; Homma S
Nihon Kokyuki Gakkai Zasshi; 2007 Jun; 45(6):489-93. PubMed ID: 17644946
[TBL] [Abstract][Full Text] [Related]
37. Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Miao J; Liu R; Li Z
Lancet; 2009 Apr; 373(9670):1171-2; author reply 1172-3. PubMed ID: 19345824
[No Abstract] [Full Text] [Related]
38. Cytochrome P-450 polymorphisms and response to clopidogrel.
Taubert D; Bouman HJ; van Werkum JW
N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
[No Abstract] [Full Text] [Related]
39. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report.
Duconge J; Cadilla CL; Renta JY; Silén-Rivera P; Piovanetti P; García-Berdecía R; Castro-Rosario LM; Monzón S; Vélez L; Rosas G; Guerra JA; Santiago-Borrero PJ
P R Health Sci J; 2008 Dec; 27(4):357-8. PubMed ID: 19069365
[No Abstract] [Full Text] [Related]
40. Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.
Seo T; Nagata R; Ishitsu T; Murata T; Takaishi C; Hori M; Nakagawa K
Pharmacogenomics; 2008 May; 9(5):527-37. PubMed ID: 18466100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
